Mariner LLC Sells 5,719 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mariner LLC cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 14.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,484 shares of the medical equipment provider's stock after selling 5,719 shares during the period. Mariner LLC's holdings in Hologic were worth $2,414,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HOLX. Barclays PLC grew its stake in shares of Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after acquiring an additional 231,578 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Hologic in the 3rd quarter worth approximately $93,000. Tidal Investments LLC raised its stake in Hologic by 60.1% during the 3rd quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock valued at $1,250,000 after buying an additional 5,764 shares during the last quarter. Franklin Resources Inc. raised its stake in Hologic by 171.7% during the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock valued at $22,714,000 after buying an additional 175,855 shares during the last quarter. Finally, Oddo BHF Asset Management Sas purchased a new position in shares of Hologic in the 3rd quarter worth $1,110,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HOLX shares. Needham & Company LLC downgraded Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Raymond James reissued an "outperform" rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic currently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $58.19 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm has a market cap of $13.06 billion, a price-to-earnings ratio of 18.36, a P/E/G ratio of 2.14 and a beta of 0.82. The firm has a fifty day moving average price of $61.34 and a 200 day moving average price of $70.45. Hologic, Inc. has a fifty-two week low of $55.89 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.